Okay, hereS a significantly expanded and restructured article based on the provided text, aiming for SEO, user value, E-E-A-T, and adherence to the specified requirements. I’ve added sections, analysis, and context. I’ve also included the required HTML elements. This is a *long* response, as it’s a full article draft.

“`html

Hepatitis B Vaccine Review sparks Controversy as Experts Feel Shut Out

WASHINGTON – the federal government’s vaccine advisory panel is scheduled to review the Hepatitis B vaccine this week, a process that has already ignited controversy. Experts on the shot – both within and outside of the government – have told STAT they’ve been largely shut out of the process, raising serious questions about transparency and the reliance on extensive scientific data.

What’s Happening: A Departure from Standard Practice

Traditionally, vaccine reviews by the Advisory Committee on Immunization Practices (ACIP) involve close collaboration with vaccine manufacturers. These companies hold crucial safety data gathered throughout the vaccine’s lifecycle, and their experts are vital for understanding manufacturing processes and potential adverse events. Though, according to three individuals familiar with the matter, this standard practice has been abandoned in the current review.

Makers of the Hepatitis B vaccine, who possess this critical safety data, haven’t been consulted by government experts as they usually are.This represents a significant departure from established protocols.

The exclusion extends to internal government experts as well. at a recent all-hands meeting of the Centers for Disease Control and Prevention’s Immunization Services Division, director Georgina Peacock informed staff that no one from the division or the broader Centre for Immunization and Respiratory Diseases would be presenting at the ACIP meeting. This is unusual, as CDC subject matter experts typically present agency data and answer committee questions.

Why This Matters: Concerns About Transparency and Scientific Rigor

The decision to exclude these experts has drawn sharp criticism from public health leaders. Critics argue that the process ignores robust scientific data supporting the use of the vaccine, lacks transparency, and potentially prioritizes political goals over public health outcomes. One source familiar with the discussions stated, “[ACIP leaders] do not appear to be interested in that aspect of the safety data.”

While government health officials have access to some safety data thru previous filings with the Food and Drug Administration (FDA), the historical practice involved direct engagement with manufacturers for deeper dives into the data and ongoing discussions. In previous years, ACIP representatives would routinely request and analyze data directly from company experts, often through multiple meetings.

The Broader Context: Increased Scrutiny of Vaccine Safety

This situation unfolds against a backdrop of increased scrutiny of vaccine safety. The Department of Health and Human Services (HHS) has publicly emphasized the importance of reviewing existing data and conducting further studies on vaccines. However, critics argue that excluding key experts undermines this stated commitment to data-driven decision-making.